Microdosing is probably the most talked-about psychedelic practice and the one we know least about. The testimonials are enthusiastic: more focus, better mood, more creativity. Controlled studies tell a much more sober story. Between the two lies an uncomfortable question: how much of what people notice is produced by the substance and how much by expectation.<\/p>\n\n\n\n
This article reviews what the research says, without enthusiasm and without contempt. It is not a guide to microdosing or an invitation to do it. The substances discussed are controlled in Spain.<\/p>\n\n\n\n
There is no official definition. The literature refers to doses of around a tenth or a twentieth of a usual dose, of psilocybin or LSD, taken several days a week for weeks or months. The idea is that you feel nothing resembling a trip and can carry on with your routine.<\/p>\n\n\n\n
In real-world practice there are two problems. The content of mushrooms varies a lot from one specimen to another, and almost no one knows precisely how much they are taking. What gets called a microdose covers very different things.<\/p>\n\n\n\n
Observational studies, based on surveys, are very consistent. People who microdose say they are in a better mood, more focused, more creative and more energetic, and some report less anxiety.<\/p>\n\n\n\n
The problem is one of method, not sincerity. The people answering those surveys have chosen to microdose, expect a benefit, know what they are taking and have usually read about what they are supposed to notice. These are the ideal conditions for an expectancy effect to appear.<\/p>\n\n\n\n
The most cited study was published in eLife in 2021<\/a>. Its authors devised a system so that 191 people who were already microdosing, with their own substance, could prepare capsules with microdoses and empty capsules at home, without knowing which one they were taking each day.<\/p>\n\n\n\n After four weeks, participants had improved in well-being and on several psychological measures. But those who took microdoses and those who took placebo improved alike, with no significant differences between groups. What best predicted feeling good was not what they had taken, but what they believed they had taken.<\/p>\n\n\n\n Several double-blind trials with low doses of LSD or psilocybin have measured mood, cognition and creativity. The overall picture: some mild acute effects on the day of dosing, little or no cumulative benefit, and null results for creativity and cognitive performance. One trial with psilocybin mushrooms found no improvements in well-being, creativity or cognition compared with placebo.<\/p>\n\n\n\n A systematic review published in 2026 in Frontiers in Psychiatry<\/a>, focused on microdosing with psilocybin mushrooms and truffles, analyzed 11 studies with 3,262 adults. Its conclusion: observational studies describe benefits, but the two placebo-controlled trials found no significant improvements. The authors also note that adverse effects are poorly recorded and that efficacy and safety remain uncertain.<\/p>\n\n\n\n With the current data, the most honest thing to say is that a large part of it is, and that a small pharmacological effect which studies have not yet managed to isolate cannot be ruled out.<\/p>\n\n\n\n There are two important nuances.<\/p>\n\n\n\n Someone who improves on placebo really does improve. The ritual of taking care of yourself, the attention you pay to your own state and the expectation of change have real effects on mood. What changes is the explanation: perhaps what helps is not in the capsule.<\/p>\n\n\n\n They are few, short and almost always conducted with healthy people. It is hard to maintain blinding, because some people notice the dose. And there are no large trials in people with depression or other problems. Better studies may find something. So far they have not.<\/p>\n\n\n\n A small dose is not a harmless one, especially because it is repeated.<\/p>\n\n\n\n On top of this comes the legal question, which we summarize in the legal status of psychedelics in Spain<\/a>.<\/p>\n\n\n\n It is common to think of microdosing as an alternative to an antidepressant or as a way of treating anxiety. There is no evidence to support this. The promising results for psilocybin in depression come from high doses, in one-off sessions and with psychological support, which is something very different. We explain it in psilocybin and depression: a summary of the clinical studies<\/a>.<\/p>\n\n\n\n Replacing a treatment with microdosing, or stopping a medication in order to start, is a real risk in exchange for an unproven benefit.<\/p>\n\n\n\n Some questions to ask yourself first:<\/p>\n\n\n\n Keeping a simple daily log, with breaks, helps you avoid mistaking a good day for an effect. And if what you are looking for is better mood or focus, sleep, exercise and social contact have considerably more support behind them.<\/p>\n\n\n\n We talk about microdosing without promises. We offer information and support<\/a> to those who decide to explore it using their own judgment: reviewing motives and expectations, tracking progress and deciding when to stop. We do not sell, supply or facilitate substances.<\/p>\n\n\n\nThe laboratory trials<\/h3>\n\n\n\n
The most recent review<\/h3>\n\n\n\n
So, is it all placebo?<\/h2>\n\n\n\n
Placebo does not mean imaginary<\/h3>\n\n\n\n
The studies have limits too<\/h3>\n\n\n\n
What is known about safety<\/h2>\n\n\n\n
\n
Microdosing and mental health<\/h2>\n\n\n\n
If you are still considering it<\/h2>\n\n\n\n
\n
How we approach it at RILOFU<\/h2>\n\n\n\n